Trastuzumab deruxtecan plus pertuzumab as a substantial advancement in previously untreated patients with HER2-positive metastatic breast cancer.
- DOI
- 10.26355/eurrev_202608_37910
- Published
- 2026 Aug
- Container
- European review for medical and pharmacological sciences
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.26355/eurrev_202608_37910,
title = {Trastuzumab deruxtecan plus pertuzumab as a substantial advancement in previously untreated patients with HER2-positive metastatic breast cancer.},
author = {Messori A and Lupi T and Gasperoni L and Del Bono L and Ossato A and Damuzzo V},
year = {2026},
journal = {European review for medical and pharmacological sciences},
doi = {10.26355/eurrev_202608_37910},
url = {https://doi.org/10.26355/eurrev_202608_37910}
}RIS
TY - JOUR TI - Trastuzumab deruxtecan plus pertuzumab as a substantial advancement in previously untreated patients with HER2-positive metastatic breast cancer. AU - Messori A AU - Lupi T AU - Gasperoni L AU - Del Bono L AU - Ossato A AU - Damuzzo V PY - 2026 JO - European review for medical and pharmacological sciences DO - 10.26355/eurrev_202608_37910 UR - https://doi.org/10.26355/eurrev_202608_37910 ER -
APA
A, M., T, L., L, G., L, D. B., A, O., & V, D. (2026). Trastuzumab deruxtecan plus pertuzumab as a substantial advancement in previously untreated patients with HER2-positive metastatic breast cancer.. European review for medical and pharmacological sciences. https://doi.org/10.26355/eurrev_202608_37910
Source records
- pubmed · retrieved 2026-09-27T06:42:50.205Z